Skip to main content

BioAtla, Inc.

BCAB
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826892

No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding BioAtla, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of BCAB: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders80165−14
Shares22.1M791.6K17.7M−3.66M (−17.2%)
Value$30.4M$1.08M$31.0M+$1.73M (+5.9%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (13)

Institutions that held BioAtla, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to BCAB in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.595,267$1.05M0.00%
Marshall Wace, LLP436,489$768.2K0.00%
Gsa Capital Partners LLP353,769$623.0K0.05%
Diametric Capital, LP83,505$147.0K0.07%
Prelude Capital Management, LLC30,410$53.5K0.00%
Simplex Trading, LLC28,490$50.0K0.00%
Chicago Partners Investment Group LLC23,217$44.1K0.00%
Vontobel Holding Ltd.16,000$28.2K0.00%
Columbia Advisory Partners LLC10,940$19.3K0.02%
Transcend Wealth Collective, LLC10,000$17.6K0.00%
Cubist Systematic Strategies, LLC7,788$13.7K0.00%
Tucker Asset Management LLC500$8800.00%
GWM Advisors LLC9$180.00%

Sold out (27)

Institutions that held BioAtla, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Not filed for Q3 2024 yet (1)

Institutions that held BioAtla, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding BCAB in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.791,560$1.08M